The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system.

Ji CH, Kim HY, Lee MJ, Heo AJ, Park DY, Lim S, Shin S, Ganipisetti S, Yang WS, Jung CA, Kim KY, Jeong EH, Park SH, Bin Kim S, Lee SJ, Na JE, Kang JI, Chi HM, Kim HT, Kim YK, Kim BY, Kwon YT. · 2022

Read The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system. by Ji CH, Kim HY, Lee MJ, Heo AJ, Park DY, Lim S, Shin S, Ganipisetti S, Yang WS, Jung CA, Kim KY, Jeong EH, Park SH, Bin Kim S, Lee SJ, Na JE, Kang JI, Chi HM, Kim HT, Kim YK, Kim BY, Kwon YT. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8850458.txt.

Introduction

Ji and co-authors build a platform that destroys chosen proteins by feeding them to the cell's recycling system. The method is called AUTOTAC. Its molecules have two ends. One end grips the target protein. The other wakes a dormant autophagy receptor, p62. The woken receptor gathers the target into bodies for disposal. The lysosome then degrades the cargo.

The team tested AUTOTACs against several cancer proteins. They also targeted stubborn protein aggregates tied to neurodegeneration. The molecules worked at nanomolar strength in cells and in living animals. Degradation came with a boost to overall autophagic flow. The authors present AUTOTAC as a general tool. It could serve basic research and drug design alike. Proteins once called undruggable are the prize.

Catalog record

CREATORJi CH, Kim HY, Lee MJ, Heo AJ, Park DY, Lim S, Shin S, Ganipisetti S, Yang WS, Jung CA, Kim KY, Jeong EH, Park SH, Bin Kim S, Lee SJ, Na JE, Kang JI, Chi HM, Kim HT, Kim YK, Kim BY, Kwon YT.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE67 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC8850458

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system By Chang Hoon Ji, Hee Yeon Kim, Min Ju Lee, Ah Jung Heo, Daniel Youngjae Park, Sungsu Lim, Seulgi Shin, Srinivasrao Ganipisetti, Woo Seung Yang, Chang An Jung, Kun Young Kim, Eun Hye Jeong Published in: Nature Communications DOI: 10.1038/s41467-022-28520-4 ABSTRACT Targeted protein degradation allows targeting undruggable proteins for therapeutic applications as well as eliminating proteins of interest for research purposes. While several degraders that harness the proteasome or the lysosome have been developed, a technology that simultaneously degrades targets and accelerates cellular autophagic flux is still missing. In this study, we develop a general chemical tool and platform technology termed AUTOphagy-TArgeting Chimera (AUTOTAC), which employs bifunctional molecules composed of target-binding ligands linked to autophagy-targeting ligands. AUTOTACs bind the ZZ domain of the otherwise dormant autophagy receptor p62/Sequestosome-1/SQSTM1, which is activated into oligomeric bodies in complex with targets for their sequestration and degradation. We use AUTOTACs to degrade various oncoproteins and degradation-resistant aggregates in neurodegeneration at nanomolar DC50 values in vitro and in vivo. AUTOTAC provides a platform for selective proteolysis in basic research and drug development. INTRODUCTION In the central dogma, the genetic information in DNA is transcribed into RNA, which in turn is translated to protein. Recent advances in genetic bioengineering, exemplified by CRISPR, TALEN, and siRNA, have enabled selective destruction and functional silencing of DNA and RNA1,2. In contrast to the universally applicable nature of DNA and RNA editing, there are currently no general tools by which proteins are selectively recognized and targeted for destruction. Functional silencing of proteins via small molecule inhibitors, while highly penetrant, rapid, and straightforward, is limited to approximately only a fifth of the entire human proteome3. Such a technology, if available, will be readily applied as research tools and agents to selectively downregulate target proteins in cultured cells and in living organisms such as mice and flies. Selective degradation of disease-associated proteins also provides an attractive opportunity to develop degrader-type drugs. Targeted protein degradation (TPD) is the latest of emerging modalities in drug discovery and development and typically employs heterobifunctional chimeric molecules comprised of a target binder linked to a degradation-inducing moiety, which offer an attractive therapeutic means to eradicate disease-associated proteins, especially those belonging to the once-considered undruggable proteome3–7. Current TPD technology, as exemplified by PROteolysis-TArgeting Chimera (PROTAC), is limited to inducing the ubiquitination of target substrate for its degradation8. Despite its advantages, however, ubiquitin (Ub)-dependent PROTAC is largely confined to a limited set of target proteins and of E3 ligases, due to technical difficulties in forming a substrate-PROTAC-E3 ternary complex9. These technical challenges, which to date have ruled out the possibility of a pan-ubiquitinating and promiscuous E3 ligase for PROTACs, limit the meaningful clinical targets of PROTAC to a handful of otherwise short-lived ubiquitinated substrates, especially oncoproteins8,10,11. Moreover, Ub-dependent PROTAC may not be an ideal TPD platform to degrade misfolded and aggregation-prone pathological protein species, such as those of neurodegenerative proteinopathies, as these protein species are typically resistant to unfolding and subsequent degradation by the proteasome due to size limitations12,13. Recent advances in the field of autophagy-based degraders or molecular glues, such as AUTAC, ATTEC, and LYTAC have been successful in degrading a number of targets via the lysosome14–17. However, LYTAC is applicable to only extracellular proteins, ATTEC directly targets mutant Htt or lipid droplets to the autophagosome without prior sequestration, and AUTAC utilizes S-guanylation that is still dependent on ubiquitination of the target14–17. These challenges of the existing TPD modalities necessitate further development of a generally applicable TPD platform independent of Ub and the proteasome. Selective macroautophagy is a catabolic process by which unwanted or harmful cytoplasmic constituents including proteins, aggregates, and organelles are specifically sequestered by autophagosomes for lysosomal hydrolysis18. Selective targeting of autophagic cargoes calls for specific receptors such as p62 and other Sequestosome-like receptors (SLRs) that simultaneously recognize Ub chains on protein cargoes and the lipidated LC3 in the autophagosomal inner membrane via the UBA and the LIR domain, respectively19. While recent efforts—such as harnessing S-guanylation-inducing molecular tags (AUTAC) or targeting extracellular and secreted/membrane proteins directly to the lysosome via peptidic tags (LYTAC)—attempt to address the degradation of PROTAC-resistant cargoes, no degrader technology yet exists for directly sequestering and targeting proteins and their aggregates using autophagy cargo receptors (e.g., p62). In the N-degron pathway, specific single N-terminal amino acids of proteins, termed N-degrons, are recognized by N-recognins to induce substrate degradation20. The arginylation branch of this pathway uses Arg, Lys, His (type 1), Phe, Tyr, Trp, Leu, and Ile (type 2) as N-terminal degrons, among which the Arg N-degron can be generated via ATE1 R-transferase-mediated conjugation of L-Arg to Asp, Glu, or oxidized Cys. Recently, we discovered that the Arg/N-degron pathway mediates not only UBR-dependent proteasomal clearance but also macroautophagic proteolysis, wherein the archetypal autophagic cargo adaptor p62/SQSTM1 acts as an N-recognin that binds type-1 and type-2 N-degrons via its ZZ domain21. Binding of the Nt-Arg residue through the p62-ZZ domain conformationally activates p62 into an autophagy-compatible form, accelerating its self-oligomerization, interaction with LC3, and autophagosome biogenesis, facilitating autophagic targeting of p62-cargo complexes in a multi-step manner21–23. Here, we developed a generally applicable degrader, AUTOTAC, by which a broad range of cellular proteins can be selectively recognized and targeted to autophagic membranes for lysosomal degradation. Central to the mode of action in AUTOTAC is the ability of the p62-binding moiety to induce a conformational activation of otherwise inactive p62 into an autophagy-compatible form. Upon binding to the p62 ligand, p62 exposes PB1 and LIR domains, which respectively facilitates p62 self-polymerization in complex with targets and its interaction with LC3 on autophagic membranes. Thus, AUTOTACs can induce the degradation of a broad range of cellular proteins including their misfolded aggregates. RESULTS Development of the AUTOTAC platform In contrast to the UPS in which each of the 800 E3 ligases possesses a specific clientele of substrates, selective autophagy employs only a handful of receptors for intracellular cargoes, amongst which p62 plays a dominant role. If a bifunctional molecule binds both a target and p62 and activate the otherwise inactive p62, any given proteins could be targeted for autophagic degradation in principle. We therefore developed autophagy-targeting ligands (ATL; p62-binding moieties) that bind and activate p62 into an autophagy-compatible form (Fig. 1a and Supplementary Fig. 1a–e). 3D structure modeling, followed by SAR (structure-activity relationship) studies, was employed on the ZZ domain of p62. Three compounds, YOK-2204, YOK-1304 and YTK-105 (Fig. 1b), showed high docking scores based on low/negative energy of the stable system (−5.8, −5.5, and −4.0 kcal/mol for YOK-1304, YOK-2204, and YTK-105, respectively) (Supplementary Fig. 2a–f) when modeled to the p62-ZZ domain. Specific residues of the ZZ domain critical for N-degron recognition, such as Phe168, Arg139, Ile127, Asp129, Asp147, and Asp149, were also identified (Supplementary Fig. 2a–f).Fig. 1Nt-Arg-mimicking p62-ZZ ligands activate p62-dependent selective macroautophagy.a A model illustrating the mode of action of autophagy-targeting ligands. b Chemical structures of autophagy-targeting ligands. c In vitro pulldown assay in HEK293T cells of the 12-mer V-BiP peptide or autophagy-targeting ligands. d In vitro p62 oligomerization assay in HEK293T cells incubated with the p62-ZZ ligands in (b). e ICC of HeLa cells treated with p62-ZZ ligands in (b) (2.5 μM, 24

Read the complete text